Wound Care Practice Acquisition and Sale (2026): Multiples, Named Buyers, & Playbook
Quick Answer
Christoph Totter · Managing Partner, CT Acquisitions
M&A advisory across 500+ active capital partners · Healthcare services M&A: wound care, MSO, specialty clinic · Updated June 6, 2026
In a 2026 wound care practice acquisition, a US wound care business typically sells for roughly 5x to 11x EBITDA, per CT Acquisitions analysis of wound care M&A. The category benefits from aging-demographic demand (diabetic ulcers, pressure injuries, post-surgical wounds), Medicare reimbursement durability, and hyperbaric oxygen therapy (HBOT) premium economics. By profile: a single-clinic wound care center ($500k-1.5M EBITDA) goes 5x-7x; a small multi-clinic group ($1.5-4M EBITDA) goes 6x-8x; a regional wound care platform ($4-12M EBITDA, multi-state) goes 7x-9x; a premium scale platform ($12M+ EBITDA, hospital-system partnerships, HBOT capability, integrated EMR) reaches 8x-11x+ EBITDA. Active buyers include Healogics (the largest US wound care management company, owned by Bain Capital + Berkshire Partners + Singapore’s GIC; ~600+ Wound Care Centers operated under hospital partnerships), Restorix Health (PE-backed, ~150 wound care centers, hospital partnership model), Vohra Wound Physicians (private, the largest US wound physician group, focuses on skilled nursing facility wound care), Mobile Wound Care (PE-backed mobile platform), Restore Hyper Wellness (PE-backed, hyperbaric + wellness consumer), plus PE sponsors (Bain Capital + Berkshire Partners + GIC, NMS Capital, Webster Equity Partners, Audax Group). The biggest multiple drivers are hospital-system partnership footprint (most wound care operates as hospital-outpatient department [HOPD]), HBOT capability and revenue percentage, payer mix (Medicare 60-70% typical), modern EMR (Net Health Wound Expert is the operator standard), and clinician retention. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.
If you own a US wound care business in 2026, hospital-outpatient wound care center, mobile wound physician group, or independent wound clinic, the M&A market is consolidated. Healogics (Bain Capital + Berkshire Partners + GIC) is the dominant US wound care management company with ~600+ Wound Care Centers operated under hospital partnerships. Restorix Health is the second-largest hospital-partnership operator. Vohra Wound Physicians dominates SNF/post-acute wound care.
What the asset is worth depends on three things: (1) hospital-system partnership footprint (HOPD economics are durable), (2) HBOT (hyperbaric oxygen therapy) capability and revenue percentage, and (3) clinician/physician bench plus modern EMR. This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.
What this guide covers
- Wound care multiples 2026: 5x-7x for single-clinic, 6x-8x for small multi-clinic, 7x-9x for regional platforms, 8x-11x+ for premium scale with hospital partnerships + HBOT.
- Active buyers: Healogics (Bain Capital + Berkshire Partners + GIC, ~600+ centers, largest US), Restorix Health (~150 centers), Vohra Wound Physicians (largest SNF wound physician group), Mobile Wound Care (PE), Restore Hyper Wellness (PE).
- PE sponsor activity: Bain Capital + Berkshire Partners + GIC (Healogics), NMS Capital, Webster Equity Partners, Audax Group.
- Multiple drivers: hospital-system partnership footprint, HBOT capability, payer mix (Medicare 60-70%), modern EMR (Net Health Wound Expert), clinician retention.
- Things that compress: weak hospital partnership base, no HBOT, owner-physician dependence, weak EMR, single-state, Medicare-only without commercial diversification.
- No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.
Named M&A transactions (2021-2025)
CT Acquisitions · 2026 Wound Care Signal
What Wound Care Buyers Pay Premium For
Across our buy-side conversations with wound care acquirers in 2026:
- HBOT capability drives multi-turn premium. Operators with hyperbaric oxygen therapy chambers and trained staff trade above non-HBOT peers because of reimbursement economics.
- Medicare reimbursement durability is buyer-priced. Wound care benefits from aging-demographic durability; operators model 5-10 year reimbursement visibility into valuation.
- Provider productivity drives operational economics. RVU-per-provider, encounters-per-day, and revenue-per-encounter drive buyer underwriting more than headline EBITDA.
Multiple at a Glance · 2026
Wound Care Sale Multiples · 2026
By scale and HBOT capability.
Source: CT Acquisitions analysis of wound care M&A. Healogics (Bain Capital + Berkshire Partners), Restorix Health, Vohra Wound Physicians + PE-backed wound care platforms.
Related Cluster GuideFor the broader medical-practice sale playbook on how to sell a medical practice, see our companion reference.
| Target | Buyer | Year | What it tells us |
|---|---|---|---|
| Healogics continued growth | Bain Capital + Berkshire Partners + GIC | 2019-2025 | Dominant US wound care platform continues hospital partnership expansion. |
| Restorix Health expansion | PE-backed | 2022-2025 | Major hospital partnership operator continues regional growth. |
| Vohra Wound Physicians | Private | 2022-2025 | Largest US wound physician group continues SNF/post-acute expansion. |
| Restore Hyper Wellness franchise growth | PE-backed franchise platform | 2022-2025 | Consumer-direct hyperbaric/wellness franchise platform scales. |
| Mobile wound care platform growth | Multiple PE platforms | 2022-2025 | Mobile wound physician platforms continue regional expansion. |
The named buyer landscape
Dominant national platforms
- Healogics (Bain Capital + Berkshire Partners + GIC), the largest US wound care management company with ~600+ Wound Care Centers operated under hospital partnerships.
- Restorix Health (PE-backed), ~150 wound care centers, hospital partnership model.
- Vohra Wound Physicians (private), the largest US wound physician group, SNF/post-acute focus.
Specialty operators
- Mobile Wound Care (PE-backed), mobile wound physician platform.
- Restore Hyper Wellness (PE-backed), hyperbaric + wellness consumer brand.
- WoundCentrics, Wound Care Education Partners, plus regional operators.
PE sponsors active in this space
- Bain Capital + Berkshire Partners + GIC (Healogics), NMS Capital, Webster Equity Partners, Audax Group, plus multiple healthcare-services PE funds.
What each buyer will pay for vs. what they reject
- Will pay premium for: hospital-system partnership footprint, HBOT capability and revenue, multi-state platform scale, modern EMR (Net Health Wound Expert), commercial payer mix (Medicare 60-70% is normal; below 50% commercial mix compresses).
- Will compress or reject: weak hospital partnership base, no HBOT capability, owner-physician dependence, legacy EMR, single-state, Medicare-only without commercial diversification, Medicare HBOT compliance issues.
Wound care practice acquisition: the audit and reimbursement diligence buyers run
In a wound care practice acquisition, the buyer is underwriting billing history as much as earnings. Expect a review of past UPIC, ZPIC, and RAC audits, debridement depth coding, skin substitute billing, HBOT documentation against the Medicare coverage rules, and payer mix. Deal structure, indemnities, and escrow then decide who carries any pre-closing overpayment exposure.
Wound care draws more Medicare scrutiny than most outpatient specialties, so buyers start with audit history. Health Law Alliance, a healthcare defense firm, advises acquirers to request every open and closed contractor audit, the practice’s responses, and any extrapolated overpayment demand or corporate integrity agreement, then test claims for debridement depth (CPT 11042 to 11047) and skin substitute application and quantity. These gaps rarely show up in a quality of earnings report. The risk is not theoretical: Healogics agreed in 2018 to pay $22.51 million to settle False Claims Act allegations that it billed Medicare for medically unnecessary services, as reported by Law360.
HBOT gets its own review. Medicare covers hyperbaric oxygen only for the conditions listed in its national coverage determination, and documentation has to show each patient qualified. Buyers will sample HBOT charts for medical necessity before they price the HBOT revenue line.
Skin substitutes are the newest diligence item. The CMS calendar year 2026 Physician Fee Schedule final rule moved most skin substitutes used in the office setting from drug-style pricing to payment as incident-to supplies. Practices and mobile wound groups whose recent revenue leaned on skin substitute application should expect buyers to restate historical earnings on the new payment basis.
Structure decides who carries the risk. In an asset purchase, the selling entity generally keeps pre-closing billing liabilities, though successor liability can still reach a buyer that simply continues the business. In a stock purchase, the claims history comes with the entity. Either way, the federal overpayment rule at 42 U.S.C. 1320a-7k(d) requires an identified overpayment to be reported and returned within 60 days, so the clock can start during post-closing integration. Sellers who run their own billing review first, and can show clean results, negotiate smaller escrows and narrower indemnities. See our medical practice sale guide and healthcare business valuation for the broader process.
The operator-level KPI playbook buyers will diligence
Service-line mix
- Outpatient wound care center visits.
- HBOT (hyperbaric oxygen therapy) sessions: Premium revenue per session ($1,500+).
- SNF/post-acute wound rounding revenue.
- Negative pressure wound therapy (NPWT) revenue.
- Cellular/tissue products (CTPs / skin substitutes) revenue.
Hospital partnership model
- Hospital partnership count and contract terms.
- HOPD billing structure.
- Contract renewal pipeline.
- Hospital-system credit quality.
Payer mix
- Medicare percentage: Typically 60-70%.
- Commercial percentage: 20-30%+ is healthy.
- Medicaid percentage.
- Single-payer concentration.
Clinical and quality
- Wound healing rates: Document 12-week healing benchmark.
- HBOT clinical indications: CMS-approved 15 conditions; document utilization.
- HBOT compliance: CMS NCD coverage requirements.
- Wound EMR: Net Health Wound Expert (operator standard), WoundExpert, Wound Care Connection.
Dangers and traps
1. Weak hospital partnership base
Most wound care operates as HOPD; partnerships are the platform foundation.
2. No HBOT capability
HBOT is the premium revenue line; operators without HBOT face structural margin disadvantage.
3. HBOT compliance and CMS NCD audits
Medicare HBOT coverage requires specific indications; over-utilization is OIG focus area.
4. Owner-physician dependence
Build the physician bench.
5. Legacy EMR
Net Health Wound Expert is non-negotiable for premium multiples.
6. Medicare-only payer mix
Commercial diversification is a multiple-builder.
7. Single-state operations
Multi-state platform path matters.
8. SNF wound rounding compliance
SNF wound physician billing has specific compliance requirements (E/M coding, documentation).
Our POV in 2026
Wound care M&A is dominated by Healogics (Bain Capital + Berkshire Partners + GIC) at ~600+ centers, with Restorix Health and Vohra Wound Physicians as the other major operators. PE sponsors continue selective regional consolidation. Premium multiples require hospital partnerships, HBOT capability, and modern EMR.
The right time to prepare is 12-18 months before going to market, lock in hospital partnerships, build HBOT capability, modernize EMR, diversify commercial payer mix.
Preparing your business for sale: 12-18 months out
- Get multi-year audited financials.
- Document hospital partnership portfolio and contract terms.
- Build HBOT capability if not present.
- Confirm HBOT CMS NCD compliance and documentation.
- Modernize EMR to Net Health Wound Expert.
- Diversify commercial payer mix.
- Build the physician/clinician bench.
- Document wound healing rates and quality metrics.
- Run a competitive process. Healogics, Restorix Health, Vohra Wound Physicians, Mobile Wound Care, plus PE sponsors (Bain Capital + Berkshire Partners + GIC, NMS Capital, Webster Equity Partners, Audax Group).
About the Author
Christoph Totter is the founder of CT Acquisitions, an M&A advisory firm working both sides of the table, headquartered in Sheridan, Wyoming. We work directly with 500+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing. Connect on LinkedIn · Get in touch
Free, No Email Required
Get a personalized valuation in 90 seconds
Answer six quick questions and we’ll give you a sector-adjusted EBITDA multiple range plus the specific factors driving your number up or down.
Open the Valuation Tool →The five pillars of how CT Acquisitions works
Sell side for owners, buy side for acquirers, plus exit planning.
No fee on buy-side introductions. Sell side paid on success.
Search funders, family offices, lower-middle-market PE, strategics.
Introductions to the right buyers only. No public listing.
You see exactly how we are paid before any work starts.
No Pitch · No Pressure
Ready to start a confidential conversation?
Tell us about your business. We’ll tell you what it’s likely worth, whether we have qualified buyers in our network, and what the next steps could look like. Terms are agreed in writing before any work starts.
Start a Confidential Conversation →Frequently asked questions
What is the typical multiple for a wound care business in 2026?
Single-clinic wound care centers ($500k-1.5M EBITDA) typically sell at 5x-7x EBITDA. Small multi-clinic groups ($1.5-4M EBITDA) go 6x-8x. Regional platforms ($4-12M EBITDA, multi-state) go 7x-9x. Premium scale platforms ($12M+ EBITDA, hospital-system partnerships, HBOT capability, integrated EMR) reach 8x-11x+.
Who are the active buyers of wound care businesses right now?
Healogics (Bain Capital + Berkshire Partners + GIC, the largest US wound care management company with ~600+ centers under hospital partnerships), Restorix Health (PE-backed, ~150 centers), Vohra Wound Physicians (largest US wound physician group, SNF focus), Mobile Wound Care, Restore Hyper Wellness. PE sponsors: Bain Capital + Berkshire Partners + GIC, NMS Capital, Webster Equity Partners, Audax Group.
What hurts a wound care business’s valuation most?
Weak hospital partnership base, no HBOT capability, HBOT compliance/NCD issues, owner-physician dependence, legacy EMR, Medicare-only without commercial diversification, single-state operations, SNF wound rounding compliance gaps.
Why is HBOT capability so important?
HBOT (hyperbaric oxygen therapy) generates $1,500+ per session revenue and is reimbursed under CMS NCD for 15 specific indications (diabetic ulcers, osteomyelitis, radiation injury, etc.). Operators without HBOT face structural margin disadvantage. Premium wound care platforms require HBOT capability.
Do I have to pay a broker fee?
No. CT Strategic Partners runs a M&A advisory model. No fee to you on buy-side introductions; sell-side mandates are paid on success at closing.
How long does it take to sell a wound care business?
Typical process 5-9 months. Add 12-18 months of preparation work before going to market.
What is the hospital partnership model?
Most US wound care operates as hospital-outpatient department (HOPD) under partnership agreements. The operator provides clinical staff, equipment, and management; the hospital provides licensure, facility, and billing infrastructure. Hospital-system partnership footprint is the durable moat for wound care platforms.
When should I start preparing if I plan to sell in 2027 or 2028?
12-18 months before going to market. Highest-leverage work: lock in hospital partnerships, build HBOT capability, modernize EMR, diversify commercial payer mix.
How is a wound care practice valued?
Most buyers value a wound care practice on adjusted EBITDA times a multiple. Adjusted EBITDA normalizes physician-owner pay to market rates and removes one-time costs. The multiple then moves with hospital partnership footprint, HBOT capability, payer mix, clinician depth, and how much revenue depends on skin substitutes, which buyers now restate under the 2026 Medicare payment rules.
Where do wound care businesses come up for sale?
Small wound clinics and mobile wound groups sometimes appear on broker listing sites, but most sales happen off-market. Hospital-partnership operators, mobile wound platforms, and healthcare private equity sponsors approach owners directly or through advisors. If you are a buyer, expect competition from those platforms; if you are a seller, a targeted process reaches them without a public listing.
Does the 2026 skin substitute payment change affect my sale price?
It can. If a large share of your recent revenue came from applying skin substitutes in an office or nursing facility setting, buyers will restate your earnings using the 2026 Physician Fee Schedule payment approach rather than your historical collections. Practices built on hospital outpatient partnerships, debridement, and HBOT are less exposed. Model the restated number before you go to market.
Related research
- How to sell a physical therapy practice
- How to sell an infusion therapy business
- How to sell a DME business
- How to sell a home health agency
- How to sell a hospice business
- How to sell a pain management practice
- Healthcare business valuation
- Which industries is PE buying most in 2026
- Private equity value creation
- Business broker alternative
